comparison of glp-1 integrated weight management platforms agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis Mapping the effectiveness and risks

Sanders et al

Current clinical trial data shows that GLP-1s lead to significant weight loss (15-20%) after one year of consistent usage

Stress Creates a Circadian Appetite Mismatch. Stress disrupts the natural timing of: cortisol GLP-1 SCFAs the conversion of serotonin to melatonin hunger/satiety hormones This results in: low morning appetite late-night cravings afternoon energy dips dysregulated eating patterns Your appetite becomes mis-timed because your microbiome is mis-timed

This move makes Noom the first weight loss company to announce on-demand fitness programming into its platform specifically to support GLP-1 patients

The bridge from "probiotic evidence in non-GLP-1 populations" to "probiotic use during GLP-1 treatment" rests on biological plausibility and the bidirectional microbiome story described above, not on direct head-to-head trials

They commonly support individuals managing diabetes, high blood pressure, high cholesterol, obesity, and digestive issues while offering preventive care strategies as well